Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2025 08:00 ET | Source: Incannex Healthcare

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding...
July 25, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing...
June 24, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

NEW YORK and MELBOURNE, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing...
May 09, 2024 08:00 ET | Source: Apnimed, Inc.

Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea

Apnimed Completes Enrollment in Ph3 LunAIRo Study of AD109, Potential 1st Nighttime Oral Tx for Obstructive Sleep Apnea; Presents Study Design at ATS2024
January 22, 2024 07:00 ET | Source: Apnimed, Inc.

Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

Apnimed Announces New Leadership Appointments as It Builds Commercial & HR Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for OSA